We are pleased to announce that Avogadro (130 staff, 11 M€ turnover), the CRO based at Toulouse, France and Cambridge, MA, USA has become associated with Amatsi a company specialised in formulation development and clinical batch manufacture, located at Montpellier, France and London, UK.
The objective of this new group is to offer a widened range of services to its clients in the following fields:
- Pharmaceutical development (pre-formulation, formulation, analytical development, stability studies).
- Pre-clinical development (bioanalysis, PK, ADME, biochemistry, residues and TAS - including in-life studies on all laboratory and veterinary species).
- Manufacture, packaging, storage and distribution of clinical batches.
- Quality control (raw materials and finished products).
André Weil, President. Jean-Pierre Arnaud, CEO.
Avogadro is an independent GLP, GMP compliant CRO established in 1998 and based in Toulouse, France and Cambridge MA, USA.
Avogadro specializes in Pharmaceutical Analysis, CMC&RA, Quality Control, In-life Phase Studies, Bioanalytical Chemistry, Drug Metabolism, Pharmacokinetics, ADME, Biochemistry, Residues and TAS.
Avogadro provides R&D services for human and veterinary pharmaceuticals, cosmetics and nutraceuticals.
Avogadro has a committed and multi-disciplinary team of 125 scientists (BSc, MSc, Engineer, Pharm.D, DVM, Ph.D) with a strong expertise in pharmaceutical R&D and a very low staff turn-over.
Avogadro has 4000 m² (45,000 sq.ft) of laboratories located on a secure site equipped with an independent power supply. Avogadro's strengths are its focus on Quality (scientific expertise, GLP, GMP, ISO14001, etc.), and its excellence in reactivity, flexibility and communication.!